Arixtra and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is reported as a side effect among people who take Arixtra (fondaparinux sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Thrombosis.

The phase IV clinical study analyzes which people have Chronic obstructive pulmonary disease when taking Arixtra. It is created by eHealthMe based on reports of 9,755 people who have side effects when taking Arixtra from the FDA, and is updated regularly.

What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 9,830 Arixtra users. Check the latest studies of Arixtra.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,807 drugs and 2,207 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.

On Jul, 28, 2026

9,755 people reported to have side effects when taking Arixtra.
Among them, 42 people (0.43%) have Chronic obstructive pulmonary disease.

Could Arixtra cause Chronic obstructive pulmonary disease?

Among these 42 people:

How long have people been on Arixtra when they have Chronic obstructive pulmonary disease? *

What is the gender of people who have Chronic obstructive pulmonary disease when taking Arixtra? *

female: 48.78 %
male: 51.22 %

What is the age of people who have Chronic obstructive pulmonary disease when taking Arixtra? *

What are other drugs people take besides Arixtra? *

What are other side effects people have besides Chronic obstructive pulmonary disease? *

Weakness: 26 people, 61.90%
Intervertebral Disc Protrusion (spinal disc protrusion): 24 people, 57.14%
Abdominal Pain: 21 people, 50.00%
Pain: 21 people, 50.00%
Urinary Tract Infection: 21 people, 50.00%
Stress And Anxiety: 21 people, 50.00%
Osteonecrosis Of Jaw (death of bone of jaw): 21 people, 50.00%
Atelectasis (partial or complete collapse of the lung): 20 people, 47.62%
Dehydration (dryness resulting from the removal of water): 20 people, 47.62%
Fever: 20 people, 47.62%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 6 people, 14.29%
Thrombosis (formation of a blood clot inside a blood vessel): 6 people, 14.29%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 11.90%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 9.52%
Gastric Ulcer (stomach ulcer): 4 people, 9.52%
High Blood Cholesterol: 4 people, 9.52%
High Blood Pressure: 4 people, 9.52%
Arrhythmias (irregular heartbeat): 4 people, 9.52%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 7.14%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and have Chronic obstructive pulmonary disease?

- Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arixtra:

Arixtra (9,830 reports)

Browse all side effects of Arixtra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (1,807 drugs)

Browse all the conditions that are associated with Chronic obstructive pulmonary disease:

Chronic obstructive pulmonary disease (2,207 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium (the active ingredients of Arixtra) and Arixtra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.